Nothing Special   »   [go: up one dir, main page]

AR095196A1 - Medio de cultivo celular libre de suero - Google Patents

Medio de cultivo celular libre de suero

Info

Publication number
AR095196A1
AR095196A1 ARP140100803A ARP140100803A AR095196A1 AR 095196 A1 AR095196 A1 AR 095196A1 AR P140100803 A ARP140100803 A AR P140100803A AR P140100803 A ARP140100803 A AR P140100803A AR 095196 A1 AR095196 A1 AR 095196A1
Authority
AR
Argentina
Prior art keywords
serum free
free cell
cell cultivation
cultivation media
ornithine
Prior art date
Application number
ARP140100803A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR095196(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR095196A1 publication Critical patent/AR095196A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/005—Protein-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/14—Calcium; Ca chelators; Calcitonin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/16—Magnesium; Mg chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La memoria descriptiva describe un medio de cultivo celular mejorado libre de suero animal, que puede usarse para la producción de una proteína de interés. La ornitina, o una combinación de ornitina y putrescina puede agregarse a medios libres de suero o medios definidos en forma química para mejorar la densidad de células viables, para reducir el tiempo de duplicación celular, y para aumentar la producción de una proteína de interés.
ARP140100803A 2013-03-15 2014-03-10 Medio de cultivo celular libre de suero AR095196A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361790136P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095196A1 true AR095196A1 (es) 2015-09-30

Family

ID=51528781

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100803A AR095196A1 (es) 2013-03-15 2014-03-10 Medio de cultivo celular libre de suero

Country Status (22)

Country Link
US (5) US20140273095A1 (es)
EP (4) EP3919611A1 (es)
JP (5) JP6781039B2 (es)
KR (6) KR102166166B1 (es)
CN (2) CN105143444A (es)
AR (1) AR095196A1 (es)
AU (4) AU2014227804B2 (es)
BR (2) BR122020021864B1 (es)
CA (5) CA2906768C (es)
DK (1) DK2970876T3 (es)
EA (3) EA202191602A3 (es)
ES (1) ES2682929T3 (es)
HK (1) HK1213289A1 (es)
HU (1) HUE040233T2 (es)
IL (5) IL300911A (es)
MX (3) MX357977B (es)
MY (1) MY175957A (es)
PL (1) PL2970876T3 (es)
PT (1) PT2970876T (es)
SG (3) SG10202107444XA (es)
TW (4) TWI782295B (es)
WO (1) WO2014144198A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
DK3122869T3 (da) * 2014-03-24 2019-09-09 Biogen Ma Inc Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
JP7030695B2 (ja) * 2015-12-03 2022-03-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 微生物の増殖または検出のための化学的に明らかな培地
KR20180047404A (ko) * 2016-10-31 2018-05-10 삼성바이오에피스 주식회사 세포 배양 배지에서 원치 않는 배양 부산물을 감소시키는 공정
CN108220334A (zh) * 2016-12-09 2018-06-29 上海迈泰君奥生物技术有限公司 无血清细胞培养基及高效表达重组蛋白质的方法
CN106635953B (zh) * 2016-12-13 2021-02-19 昆明润什生物科技有限公司 无血清无蛋白细胞培养基
US11248054B2 (en) 2017-06-12 2022-02-15 Bluefin Biomedicine, Inc. Anti-IL1RAP antibodies and antibody drug conjugates
WO2019010191A1 (en) * 2017-07-06 2019-01-10 Regeneron Pharmaceuticals, Inc. CELL CULTURE METHOD FOR PRODUCING GLYCOPROTEIN
CN108103003B (zh) * 2017-12-12 2021-03-05 四川百诺吉科技有限公司 一种适应pk-15全悬浮生长的无血清培养基及其制备方法和应用于pk-15细胞的全悬浮驯化方法
WO2019135238A1 (en) * 2018-01-03 2019-07-11 Technion Research & Development Foundation Limited Naive pluripotent stem cell media
US10961500B1 (en) * 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
WO2020229584A1 (en) * 2019-05-16 2020-11-19 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
CN110438066B (zh) * 2019-08-19 2021-01-12 杭州百凌生物科技有限公司 一种可稳定传代的可悬浮培养的哺乳动物细胞系293 c18p及其制备方法和应用
MY190625A (en) 2019-12-06 2022-04-27 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
IL303596A (en) 2020-01-21 2023-08-01 Regeneron Pharma Deglycosylation methods for electrophoresis of glycosylated proteins
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
CA3192999A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
US12031151B2 (en) 2021-01-20 2024-07-09 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
KR20220127465A (ko) 2021-03-11 2022-09-20 주식회사 만도 조향 제어 장치 및 방법

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072565A (en) 1974-11-04 1978-02-07 The Dow Chemical Company Production of viruses in tissue culture without use of serum
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
EP0082974B1 (en) 1981-12-24 1986-05-14 Asahi Kasei Kogyo Kabushiki Kaisha Method for the cultivation of normal diploid cells and cultivation medium used therefor
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
DE3801236A1 (de) 1988-01-18 1989-07-27 Boehringer Mannheim Gmbh Pentosansulfat-medium
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5529920A (en) 1988-12-14 1996-06-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human liver epithelial cell line and culture media therefor
AU621972B2 (en) 1988-12-14 1992-03-26 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Cell culture medium for human liver epithelial cell line
DE59010933D1 (de) 1989-09-12 2003-05-08 Hoffmann La Roche TFN-bindende Proteine
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5426699A (en) 1993-10-25 1995-06-20 Antec Corporation Method and apparatus for digitizing a scrambled analog video signal
EP0666312A1 (en) 1994-02-08 1995-08-09 Wolfgang A. Renner Process for the improvement of mammalian cell growth
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
AU6698496A (en) 1995-07-17 1997-02-18 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Metal-containing ribonucleotide polypeptides
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6043092A (en) 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
US6146847A (en) 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
CA2318376A1 (en) 1998-01-12 1999-07-15 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
AU3877800A (en) 1999-03-30 2000-10-16 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
ATE417928T1 (de) * 1999-06-08 2009-01-15 Regeneron Pharma Vegf-rezeptorchimären zur behandlung von augenkrankheiten, welche durch vaskuläre permeabilität charakterisiert sind.
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CN1114619C (zh) * 1999-06-25 2003-07-16 中国科学院上海细胞生物学研究所 小鼠杂交瘤株Hepama－1分泌的肝癌鼠源单克隆抗体的制备方法
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2434802C (en) 2001-01-16 2013-05-28 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
WO2002069733A1 (en) 2001-03-05 2002-09-12 Council Of Scientific And Industrial Research Process for preparation of protein-hydrolysate from soy flour
EP1321515A1 (en) * 2001-12-21 2003-06-25 Ingenium Pharmaceuticals AG Method of culturing cells
CN1180080C (zh) * 2002-01-18 2004-12-15 中国科学院上海细胞生物学研究所 一种改进的肝癌鼠源单克隆抗体的制备方法
DE60309238T2 (de) 2002-03-08 2007-06-06 Asml Netherlands B.V. Lithographische Maske, lithographischer Apparat und Verfahren zur Herstellung einer Vorrichtung
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
EP1531666B1 (en) 2002-05-29 2013-10-23 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
PL1623019T5 (pl) 2003-05-15 2018-02-28 Wyeth Llc Ograniczone zasilanie glukozą w hodowli komórek zwierzęcych
WO2005010160A2 (en) 2003-07-17 2005-02-03 Wisconsin Alumni Research Foundation Liquid crystals with reduced toxicity and applications thereof
KR20060076781A (ko) 2003-09-18 2006-07-04 레이븐 바이오테크놀로지스, 인코퍼레이티드 세포 배양 배지
DK1767546T3 (da) 2004-06-08 2012-04-23 Chengdu Kanghong Biotechnologies Co Ltd Angiogenese-inhiberende kimært protein og dets anvendelse
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US7598083B2 (en) 2004-10-29 2009-10-06 Centocor, Inc. Chemically defined media compositions
US8273553B2 (en) 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
AU2007204044B2 (en) * 2006-01-04 2012-09-27 Takeda Pharmaceutical Company Limited Oligopeptide-free cell culture media
DE602007008627D1 (de) * 2006-02-14 2010-10-07 Genetix Ltd Zellkulturmedium
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN101454345B (zh) 2006-06-02 2012-08-08 瑞泽恩制药公司 人il-6受体的高亲和力抗体
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN104152395B (zh) * 2006-11-08 2020-03-10 惠氏公司 合理设计的细胞培养基
ES2522615T3 (es) 2007-06-04 2014-11-17 Regeneron Pharmaceuticals, Inc. Regiones de expresión y estabilidad potenciadas
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
JP5588865B2 (ja) 2007-07-31 2014-09-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｃｄ２０に対するヒト抗体及びその使用方法
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
CN100482786C (zh) * 2007-12-28 2009-04-29 天津百若克医药生物技术有限责任公司 一种人胚肾293细胞扩增无蛋白培养基
US8637312B2 (en) 2008-01-09 2014-01-28 Cellca Gmbh Mammalian culture media with polyamine and iron
US20110229933A1 (en) * 2008-09-26 2011-09-22 SAchering Corporaton High titer antibody production
US20100120093A1 (en) 2008-11-12 2010-05-13 Baxter International Inc. Method of Producing Serum-Free Insulin-Free Factor VII
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA2764370C (en) 2009-06-02 2018-08-21 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
CN101603026B (zh) 2009-06-19 2011-01-19 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
SI2975051T1 (sl) 2009-06-26 2021-08-31 Regeneron Pharmaceuticals, Inc. Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom
IN2012DN00801A (es) * 2009-07-31 2015-06-26 Baxter Int
ES2776980T3 (es) * 2009-12-23 2020-08-03 Merck Sharp & Dohme Línea celular 3M
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CN102834111B (zh) 2010-02-24 2014-11-12 齐姆内克斯公司 用于生产和纯化重组溶酶体α-甘露糖苷酶的方法
CN107254499B (zh) 2010-04-26 2021-09-17 诺华股份有限公司 改进的细胞培养方法
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
CA2800728C (en) 2010-05-28 2020-10-27 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
BR112013000512A2 (pt) * 2010-07-08 2016-05-17 Baxter Healthcare Sa método para produzir uma composição de adamts 13 (ra13) recombinante, sobrenadante de cultura de célula, e , composição adamts13 recombinante (ra13)'
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
US20130224855A1 (en) 2010-08-31 2013-08-29 Abhishek Gupta Culture medium for eukaryotic cells
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
EP2624865B1 (en) 2010-10-06 2018-08-01 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
KR101903208B1 (ko) 2010-12-28 2018-10-01 추가이 세이야쿠 가부시키가이샤 동물 세포의 배양 방법
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
HUE038570T2 (hu) 2011-11-14 2018-10-29 Regeneron Pharma Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával
EA033387B1 (ru) 2012-01-23 2019-10-31 Regeneron Pharma СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
JP6090735B2 (ja) 2012-03-02 2017-03-08 国立大学法人山口大学 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
CA2875294C (en) 2012-04-25 2021-06-08 Riken Cell preparation containing myocardium-committed cell
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
ES2829968T3 (es) 2012-06-21 2021-06-02 Takeda Pharmaceuticals Co Filtración de virus de medios de cultivo celular
CN104853763A (zh) 2012-08-02 2015-08-19 赛诺菲 包含阿柏西普或ziv-阿柏西普的制品
AU2013302925B2 (en) 2012-08-13 2018-07-05 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
SG11201503085VA (en) 2012-10-23 2015-05-28 Genzyme Corp Perfusion culturing methods and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
CN105209603A (zh) 2013-02-22 2015-12-30 建新公司 微载体灌注培养方法及其用途
CA2904125C (en) 2013-03-12 2022-06-07 Cmc Icos Biologics, Inc. Improved recombinant protein expression using a hybrid chef1 promoter
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
CA2902581C (en) 2013-03-14 2023-08-08 Katie Streicher Recombinant polypeptide production
JP6404314B2 (ja) 2013-03-15 2018-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−３３拮抗薬とその使用法
US20160237400A1 (en) 2013-03-15 2016-08-18 The Jackson Laboratory Isolation of non-embryonic stem cells and uses thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
JP6594860B2 (ja) 2013-05-29 2019-10-23 エフ．ホフマン−ラ ロシュ アーゲー シアル酸付加の定量的調節
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
MX2016009084A (es) 2014-01-13 2016-10-13 Amgen Inc Regulacion del metabolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteinas recombinantes.
WO2015184009A1 (en) 2014-05-27 2015-12-03 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
US9475875B2 (en) 2014-03-11 2016-10-25 Regeneron Pharmaceuticals, Inc. Anti-EGFRvIII antibodies and uses thereof
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
WO2015171523A1 (en) 2014-05-05 2015-11-12 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
CA2951025A1 (en) 2014-06-03 2015-12-10 Lupin Limited Cell culture process for producing a protein
US9657099B2 (en) 2014-09-16 2017-05-23 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
CN114807010A (zh) 2015-04-01 2022-07-29 勃林格殷格翰国际公司 细胞培养基
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
TW202140776A (zh) 2016-04-26 2021-11-01 美商美國泰福生技股份有限公司 細胞培養基
WO2019010191A1 (en) 2017-07-06 2019-01-10 Regeneron Pharmaceuticals, Inc. CELL CULTURE METHOD FOR PRODUCING GLYCOPROTEIN

Also Published As

Publication number Publication date
BR112015022682A2 (pt) 2017-07-18
KR20240065185A (ko) 2024-05-14
TW201502273A (zh) 2015-01-16
JP6944969B2 (ja) 2021-10-06
TWI701333B (zh) 2020-08-11
AU2022211862A1 (en) 2022-08-25
MX2021001859A (es) 2021-04-19
EA202191602A3 (ru) 2021-12-31
AU2014227804A1 (en) 2015-09-24
BR122020021864B1 (pt) 2022-09-20
CA2906768C (en) 2022-08-30
BR112015022682B1 (pt) 2023-03-28
NZ711935A (en) 2021-04-30
KR102229380B1 (ko) 2021-03-18
EA202191602A2 (ru) 2021-08-31
KR20210031778A (ko) 2021-03-22
EP3919611A1 (en) 2021-12-08
HUE040233T2 (hu) 2019-02-28
DK2970876T3 (en) 2018-08-13
CA2906768A1 (en) 2014-09-18
CA3135232C (en) 2024-06-18
KR102166166B1 (ko) 2020-10-15
AU2021205088A1 (en) 2021-08-12
TWI782295B (zh) 2022-11-01
MX357977B (es) 2018-08-01
JP2019150037A (ja) 2019-09-12
TW201835325A (zh) 2018-10-01
ES2682929T3 (es) 2018-09-24
KR20210090732A (ko) 2021-07-20
JP2024001357A (ja) 2024-01-09
EP4159841A1 (en) 2023-04-05
IL241195A0 (en) 2015-11-30
CA3188491A1 (en) 2014-09-18
WO2014144198A1 (en) 2014-09-18
IL289724B1 (en) 2023-04-01
EA201591817A1 (ru) 2016-05-31
JP7429743B2 (ja) 2024-02-08
JP2022172390A (ja) 2022-11-15
CA3238123A1 (en) 2014-09-18
CA3135232A1 (en) 2014-09-18
IL281515A (en) 2021-04-29
IL289724B2 (en) 2023-08-01
KR20220116571A (ko) 2022-08-23
SG10202107444XA (en) 2021-08-30
SG11201507072TA (en) 2015-10-29
AU2020200052A1 (en) 2020-01-30
CA3238121A1 (en) 2014-09-18
EP2970876A1 (en) 2016-01-20
IL300911A (en) 2023-04-01
EP2970876B1 (en) 2018-07-11
EA202190326A2 (ru) 2021-05-31
IL281515B1 (en) 2024-01-01
TW202041672A (zh) 2020-11-16
KR20150128785A (ko) 2015-11-18
JP2021180682A (ja) 2021-11-25
EA202190326A3 (ru) 2021-09-30
CN105143444A (zh) 2015-12-09
PL2970876T3 (pl) 2018-11-30
MX2015013176A (es) 2016-04-07
PT2970876T (pt) 2018-10-22
EP3378932A1 (en) 2018-09-26
SG10201707153UA (en) 2017-10-30
MY175957A (en) 2020-07-16
KR102278316B1 (ko) 2021-07-19
CN113481148A (zh) 2021-10-08
US20220372436A1 (en) 2022-11-24
US11970724B2 (en) 2024-04-30
IL289724A (en) 2022-03-01
TWI629359B (zh) 2018-07-11
MX2021008627A (es) 2022-06-14
IL264499A (en) 2019-02-28
US20200149081A1 (en) 2020-05-14
KR20200119894A (ko) 2020-10-20
IL281515B2 (en) 2024-05-01
AU2014227804B2 (en) 2020-01-30
US20210332402A1 (en) 2021-10-28
IL241195B (en) 2019-05-30
US20140273095A1 (en) 2014-09-18
JP6781039B2 (ja) 2020-11-04
AU2020200052B2 (en) 2023-01-19
US11332771B2 (en) 2022-05-17
JP2016514452A (ja) 2016-05-23
TW202325723A (zh) 2023-07-01
HK1213289A1 (zh) 2016-06-30
EA037568B1 (ru) 2021-04-15
US20220228187A1 (en) 2022-07-21
AU2021205088B2 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
AR095196A1 (es) Medio de cultivo celular libre de suero
CR20180525A (es) Producción de ácido ribonucleico libre de células
AR105602A1 (es) Medio de cultivo celular suplementado con taurina y métodos de utilización
CR20150658A (es) Montajes de mezcla que incluyen impulsores magnéticos
TR201904270T4 (tr) Tanımlı koşullar altında insan pluripotent kök hücrelerinin hematoendotelyal farklılaşması için yöntemler ve materyaller.
BR112015031637A2 (pt) conjuntos de mistura incluindo impelidores magnéticos
CY1118885T1 (el) Συνθετικες πεπτιδογλυκανες που δεσμευουν υαλουρονικο οξυ, παρασκευη, και μεθοδοι χρησης
UY34885A (es) Proteínas de unión anti-mesotelina
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
CL2010000691A1 (es) Sistemas, dispositivos y/o metodos para gestionar cojinetes magneticos.
UY4230Q (es) Bocadillo retorcido para mascota
CL2017002427A1 (es) Producción de ácido ribonucleico libre de células.
CY1118893T1 (el) Μεθοδοι ταυτοποιησης αντισωματων με μειωμενη ανοσογονικοτητα
UY34167A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
RS54073B1 (en) STROMAL MATERIAL CELLS
AR081151A1 (es) Metodo para producir bacterias pertenecientes al genero bifidobacterium
UY34335A (es) ?dispositivos, sistemas, y métodos para procesar materiales heterogéneos?.
UY34371A (es) Moléculas de ácido nucleico que se dirigen a rps6 y confieren resistencia a plagas de coleópteros.
MX2015010943A (es) Metodos de cultivo por perfusión con microportadores y usos de los mismos.
MX2019009189A (es) Metodos de cultivo por perfusion con microportadores y usos de los mismos.
BR112014014279A8 (pt) método para obter dados úteis para o diagnóstico e/ou prognóstico de insuficiência renal aguda; uso de pelo menos um micro-rna; kit para o diagnóstico e/ou prognóstico de insuficiência renal aguda e uso do kit
AR086030A1 (es) Metodos y dispositivos para amplificar acidos nucleicos
BR112016006063A2 (pt) método para clarificação de uma colheita de cultura celular em bruto
MX2016008345A (es) Produccion de anticuerpos ex vivo.

Legal Events

Date Code Title Description
FC Refusal